Articles tagged with Drug Resistance
Researchers at Children's Hospital of Philadelphia have developed a new treatment that shows long-term remissions in 80% to 100% of mice with drug-resistant or high-risk solid tumors. The treatment is less toxic than conventional chemotherapy, with fewer side effects.
Scientists developed an injectable HIV drug that blocks infection and provides extended viral suppression with lower doses and reduced side effects. The drug, CPT31, has great potential to help patients with drug resistance and those who would benefit from a longer-acting treatment option.
A new study suggests that repurposing cancer drugs to target human enzymes could lead to effective treatments for COVID-19, while reducing the risk of drug resistance. This approach has the potential to save years of research and millions of dollars in development costs.
A new computational model called TransComp-R has been developed to improve the translation of drugs from animal studies to human clinical trials. The model identified an overlooked biological mechanism possibly responsible for a patient's resistance to infliximab, a drug for inflammatory bowel diseases.
Researchers have discovered a new broad-spectrum method to treat human herpes viruses by targeting their physical properties rather than proteins. This approach prevents genes from leaving the virus and infecting cells, making it effective against resistant strains.
Researchers developed a stable 'mirror-image' peptide that effectively blocks the interaction between TIGIT and its ligand PVR, inhibiting tumor growth and metastasis. This approach offers an alternative point of attack for cancer immunotherapy, potentially outperforming existing anti-PD-1 therapy.
Researchers found that a low-dose combination of four inhibitors is more effective in treating NSCLC with EGFR mutation. The therapy, called MLD, inhibits the action of multiple proteins in the same signaling pathway, blocking cell proliferation and tumor growth.
Researchers discovered resistance to tumor inhibitors arises from gradual adaptation to selective pressures, providing opportunity for effective therapies. The study advances in evolution of resistance and offers evolutionary-informed therapies for future treatments.
Researchers analyzed 442 AML samples to identify immune classes that predict drug resistance and response to immunotherapy. IFN-γ-dominant AML patients showed strong responses to flotetuzumab and improved survival rates, highlighting the potential for T cell-targeting therapies.
Myeloma Drug Sensitivity Testing (My-DST) uses liquid biopsies to test drug effectiveness on patient samples. The approach shows promise in predicting real patient responses, and may guide drug development for multiple myeloma treatment.
Researchers at UCLA Jonsson Comprehensive Cancer Center found that combining toll-like receptor 9 agonists and NKTR-214 with PD-1 blockade can induce a potent immune reaction against resistant tumors. This combination therapy is being assessed in human clinical trials to improve cancer immunotherapy outcomes.
Researchers will sequence parasitic worm genomes to develop genetic tools for monitoring and tracking resistance, leading to new therapies. Two projects focus on river blindness and fascioliasis, causing devastating illness in millions of people globally.
Researchers found that combining rosiglitazone, a popular but abandoned diabetes treatment, with another drug called Compound A can enhance its effectiveness while reducing side effects such as weight gain and fluid retention. The study suggests that using lower doses of rosiglitazone may be sufficient to achieve similar results.
Scientists have discovered that malaria parasites have an intrinsic clock controlling their invasion of human cells. This finding opens up new avenues for treating the disease by disrupting its biological rhythms.
A study published in JAMA Network Open found that more than half of Americans starting highly regulated opioids may be receiving inappropriate treatment. The research team used pharmacy and medical claims data to identify nearly 300,000 instances of prescriptions for medications reserved for people with opioid tolerance. However, less ...
Researchers have discovered a new antiviral drug called EIDD-2801 that could change the way doctors treat COVID-19. The drug has shown promise in reducing lung damage and has been found to be effective in mice infected with SARS-CoV-2.
Researchers have discovered a new drug, FL118, that effectively treats and reverses treatment resistance in advanced multiple myeloma. The drug has shown promise in treating cancer cells from both newly diagnosed and relapsed or treatment-resistant patients.
Engineers have developed a method to predict which mutations will occur in people, making it easier to create effective pharmaceuticals. The researchers used algorithms similar to those used in chemical physics to model how evolution works and found that biased random events play a big part in the evolution of resistance in leukemia.
A new mass cytometry technique has identified key proteins in blood cancer cells, revealing why some cells are resistant to standard anti-cancer drugs. The research team hopes to apply this protocol to clinical trials to better understand why some cancers are resistant to therapies and match patients with more effective treatments.
Researchers identified a gene, CELSR2, associated with glucocorticoid resistance in leukemia cells. A new drug, venetoclax, may reverse resistance by inhibiting a cell death pathway. The findings suggest combining venetoclax with current therapy could improve ALL chemotherapy effectiveness.
Researchers discovered a new function of neurofibromatin, directly repressing estrogen receptor-alpha expression and causing treatment resistance in ER+ breast cancer. A combination therapy of SERD and MEK inhibitor was shown to be effective in animal models and is being tested in clinical trials.
The Pangaia project at Bielefeld University is developing new algorithms to analyze genomic data for biomedicine, enabling faster detection of infectious strains and hereditary diseases. Researchers can compare a single genome with thousands of others in a single step, highlighting similarities and differences.
Researchers discover potential superbug-killing compound AB569 that targets priority pathogens and additional bacteria causing foodborne illness. The compound has shown promising results in treating a wide range of infections, including those caused by Pseudomonas aeruginosa.
Researchers have identified two leukemia drugs that could be used to treat lung cancer patients with triple mutant EGFR, a type of non-small cell lung cancer. The drugs, gilteritinib and midostaurin, were found using a new live cell-based method developed by the University of Toronto team.
Researchers at KAIST have discovered mechanisms that fuel a 'domino effect' in cancer drug resistance, enabling failed responses to paclitaxel to speed up the evolution of resistance to other drugs. The study suggests a new strategy for improving second-line cancer treatment.
Researchers discovered that combining alectinib with EGFR-inhibitors prevents CNS metastasis progression in mouse model. This combination treatment overcomes alectinib resistance, offering potential novel therapies for NSCLC and secondary cancers.
Researchers at the Francis Crick Institute have discovered the mechanism behind HIV's resistance to a widely-prescribed group of drugs. By exploring the structure of integrase using cryo-electron microscopy, they found that the virus can weaken the bond between the drug and its target, enabling its key enzyme to work again.
Researchers at Florida State University College of Medicine have discovered the mechanism responsible for how two widely used antiviral drugs inhibit viruses, including HIV and hepatitis B. This breakthrough could lead to the development of more potent and effective treatments for millions of people worldwide.
A Brazilian research team identified the presence of mutant p53 protein clusters in chemotherapy-resistant glioblastoma cells, which can lead to drug resistance. The study found that these clusters are organized in a way that makes them resistant to temozolomide, a common treatment for the disease.
Researchers discovered that Kelch13 protein mutations can lead to parasite resistance by reducing hemoglobin uptake and ART activation. The findings provide critical insights into the development of more effective antimalarial treatments.
A recent study found that consistent use of nasal saline and corticosteroid sprays can significantly reduce the need for antibiotics and oral steroids in individuals with chronic rhinosinusitis (CRS). This reduction can lead to fewer side effects associated with these medications, such as gastric issues and mood disturbances. By using ...
Salk researchers found that mitochondria trigger molecular alarms when cells are stressed, which can lead to increased resistance to chemotherapy. This discovery may pave the way for new cancer treatments that target mitochondrial stress.
Researchers at UCLA Jonsson Comprehensive Cancer Center found that inhibiting PAK4 gene overcomes resistance to anti-PD-1 therapy in preclinical models. Biopsies from patients with melanoma showed high expression of PAK4, correlating with suppressed immune cell infiltration into tumors.
Researchers aim to understand how ecological and evolutionary mechanisms contribute to lung cancer development and progression, potentially leading to new treatment options. The team will investigate patterns in drug sensitivity and resistance to identify molecular hallmarks that predict treatment changes.
Researchers have identified the source of nitrogen in host blood cells that enables TB to grow and spread. Preventing access to this nitrogen could halt the disease in humans.
Researchers at McGill University identified a key protein that promotes resistance to chemotherapy in triple negative breast cancer. Targeting this protein, perilipin4, causes nearly all resistant cells to stop growing and die, holding promise for treating more patients with chemotherapeutic resistant TNBC.
Researchers have discovered that malaria parasites use a specific protein to evade frontline treatment, leading to rapid development of antimalarial resistance. The study suggests ways to restore potency and monitor for emerging resistance in Southeast Asia.
A study by University of Wisconsin-Madison researchers found that a new flu drug, baloxavir, can drive drug resistance in H3N2 and H1N1 influenza viruses. The mutation occurred in nearly 23% of patients treated with the medication, but did not appear to affect its effectiveness against other virus-fighting drugs.
The study found that API-5 is overexpressed in chemoresistant TNBC, associated with increased micro-vessel density and enhanced cell survival. A peptide targeting API-5 shows promise as an innovative treatment option for this aggressive cancer type.
Researchers discovered that SNAP, a nitric oxide donor, overcomes TMZ resistance in glioblastoma multiforme (GBM) cells by reducing MGMT protein stability. This finding offers a potential strategy to improve treatment outcomes for patients with GBM.
Researchers found that API-5 was overexpressed in endothelial cells of patients with chemoresistant TNBC, associated with increased micro-vessel density. API-5 promotes cell survival and cancer growth by inhibiting apoptosis.
A study of over 24,000 Swedish adults found that those with a family history of schizophrenia and lower IQ are more likely to experience treatment-resistant schizophrenia. The condition is associated with higher risk for suicide and significant health costs.
A new study by Massachusetts General Hospital researchers highlights the risk of drug-resistant E. coli infections in patients receiving fecal microbiota transplants, particularly those who are immunocompromised. The study's findings emphasize the need for improved donor screening to prevent transmission of these resistant organisms.
A recent study uses whole-genome sequencing to understand the evolutionary history of an XDR-TB strain that emerged in KwaZulu-Natal, South Africa. The research identifies key factors contributing to its spread, including HIV coinfection and human migration, highlighting the importance of early detection and containment strategies.
A new antiviral drug blocks RNA polymerase, inducing mutations in the genetic material of the influenza virus and rendering it nonfunctional. The study found the drug to be highly efficacious against various strains of the flu, including seasonal and pandemic viruses.
Researchers have identified a new mechanism by which cancer cells become resistant to ferroptosis, a type of cell death. A molecule called FSP1 acts as a lipid antioxidant, rescuing cancer cells from ferroptosis even when they are starved of GPX4.
Scientists have developed a new class of drug that blocks the APOBEC3B enzyme in cancer cells, which is responsible for treatment resistance. This discovery has the potential to support existing cancer therapies and make treatments more effective by targeting cancer evolution.
Researchers found that differences at the single-cell level can predict responses to BRAF inhibitor therapy, and leveraging these differences may improve patient outcomes. Maintaining a population of cells within the drug-sensitive State 1 was critical to maintaining drug sensitivity.
A randomized controlled trial demonstrates Wirelessly Observed Therapy (WOT) superior to directly observed therapy (DOT) in boosting TB treatment adherence, with all patients cured and preferring WOT. The novel technology allows for private medication taking while preserving patient autonomy and enabling targeted treatment support.
Researchers used a new technique to identify genetic profiles of individual cells in a breast cancer tumor and found a drug combination that reversed resistance. The study suggests that clinicians could begin combination therapy before resistance occurs, given the effectiveness of the additional drug.
A team of scientists developed a technique using light to activate an Iridium-based compound that cuts off the 'power source' in cancer cells, even under hypoxia. This method could reduce side effects and potentially immunize against future cancers.
A study published in Annals of Neurology found that the spread of seizures through the brain can be suppressed by a
Researchers have designed a new class of modified pantothenamides that stop malaria parasites from replicating in humans and preventing transmission to mosquitoes. These compounds are effective against malaria parasites resistant to currently available drugs.
Biomedical engineers at Duke University developed a method to overcome limitations of gene-targeted cancer drugs by combining CRISPR/Cas9 targeting with sustained release drug delivery. This strategy effectively addressed potency, elimination, and resistance issues, demonstrating improved efficacy in mice with colorectal cancers.
A study of 284 patients found that those with more severe OSA had higher blood pressure, especially at night. The researchers suggest that clinicians should consider performing a sleep study in patients with resistant hypertension to treat OSA and lower blood pressure.
A systematic review and meta-analysis suggests that people with drug-resistant epilepsy have better prospects of being seizure-free if they undergo surgical treatment at an earlier stage. The study found a 15-21% higher probability of attack freedom for those who underwent surgery early compared to later stages.
Researchers at Trinity College Dublin have discovered new biological targets that may help combat cancers resistant to existing drugs. The study, published in Molecular Cell, reveals the importance of 'accessory components' in targeting Polycomb genes and their role in regulating cellular identity.
Researchers have identified a peptide from an Antarctic sponge that shows promise as a lead for new therapies against malaria. The compound, friomaramide, effectively blocked the development of the malaria parasite in liver cells without harming them.
A clinical study comparing liquid and tissue biopsies finds multiple resistance mechanisms in individual patients, which could explain why targeted therapies often fail. The results suggest possible molecular mechanisms underlying drug resistance, pointing the way to new and more personalized therapeutics.
Researchers at Cold Spring Harbor Laboratory have discovered a way to tackle the development of resistance in pancreatic cancer by targeting the ERBB signaling pathway. This approach has shown promise in shrinking pancreatic tumors in mice, providing a potential avenue for overcoming resistance and improving treatment outcomes.